| Mycosis Fungoides
Poteligeo vs Valchlor
Side-by-side clinical, coverage, and cost comparison for mycosis fungoides.Deep comparison between: Poteligeo vs Valchlor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsValchlor has a higher rate of injection site reactions vs Poteligeo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Valchlor but not Poteligeo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Poteligeo
Valchlor
At A Glance
IV infusion
Every 1-2 weeks
CCR4 antagonist
Topical
Once daily
Alkylating agent
Indications
- Mycosis Fungoides
- Sezary Syndrome
- Mycosis Fungoides
Dosing
Mycosis Fungoides, Sezary Syndrome 1 mg/kg IV infusion over at least 60 minutes on days 1, 8, 15, and 22 of the first 28-day cycle, then on days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity.
Mycosis Fungoides Apply a thin film once daily to completely dry skin at least 4 hours before or 30 minutes after showering; stop for skin ulceration, blistering, or moderately-severe/severe dermatitis and restart at reduced frequency (once every 3 days) upon improvement, advancing to every other day then once daily if tolerated.
Contraindications
—
- Known severe hypersensitivity to mechlorethamine, including anaphylaxis
Adverse Reactions
Most common (>=20%) Rash/drug eruption, infusion related reactions, fatigue, diarrhea, upper respiratory tract infection, musculoskeletal pain
Serious Pneumonia, sepsis, pyrexia, skin infection, hepatitis, pneumonitis, infusion related reaction, lower respiratory tract infection, renal insufficiency
Postmarketing Immune-mediated colitis, hepatitis B virus reactivation, stress cardiomyopathy, granuloma
Most common (>=5%) Dermatitis, pruritus, bacterial skin infection, skin ulceration or blistering, skin hyperpigmentation
Serious Mucosal or eye injury, non-melanoma skin cancer, secondary exposure to caregivers
Pharmacology
Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4 and depletes CCR4-expressing T-cell malignancy cells, regulatory T-cells, and Th2 T-cell subsets via antibody-dependent cellular cytotoxicity (ADCC).
Mechlorethamine (nitrogen mustard) is an alkylating agent that inhibits rapidly proliferating cells; systemic exposure is undetectable after topical administration.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Poteligeo
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
Valchlor
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Poteligeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Valchlor
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Poteligeo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Valchlor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: Hodgkin's Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PoteligeoView full Poteligeo profile
ValchlorView full Valchlor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.